Sacituzumab govitecan for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 22 Sep 2020: Trial registered, NCT04559230
  2. 6 Jan 2022: Trial started, NCT04559230

The trials

NCT01631552: Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

State
Completed
Phase
Phase 1 and Phase 2
People
515 taking part
Started
17 Dec 2012
Primary completion
1 Mar 2019
Arms
Sacituzumab Govitecan-hziy (SG) 8 mg/kg, SG 10 mg/kg, SG 12 mg/kg, SG 18 mg/kg
Results
Posted on the registry
  1. 29 Jun 2012: Trial registered
  2. 17 Dec 2012: Trial started
  3. 13 Aug 2020: Trial completed
  4. 6 Apr 2021: Trial results posted

NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

State
Under way
Phase
Phase 2
People
32 planned
Started
6 Jan 2022
Primary completion
Aug 2027
Arms
Sacituzumab govitecan
Results
None posted
  1. 22 Sep 2020: Trial registered
  2. 6 Jan 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Sacituzumab Govitecan-hziy (SG).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.